Phase 1 trials of the agent will launch in 2025 to evaluate its safety, tolerability, and antitumor activity. The FDA has cleared the IND application for MRANK-106, allowing for the initiation of ...
A recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem ...
Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback